TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report

SCLC transformation in EGFR-mutated lung adenocarcinoma is one of the major phenotypic changes that is observed during the resistance to EGFR tyrosine kinase inhibitors. However, the mechanism of this transformation remains unclear. In this study, we found a small de novo SCLC component in surgicall...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunimasa, Kei, Hirotsu, Yosuke, Amemiya, Kenji, Nakamura, Harumi, Nishino, Kazumi, Honma, Keiichiro, Okami, Jiro, Omata, Masao, Kumagai, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052150/
https://www.ncbi.nlm.nih.gov/pubmed/35498386
http://dx.doi.org/10.1016/j.jtocrr.2022.100305
Descripción
Sumario:SCLC transformation in EGFR-mutated lung adenocarcinoma is one of the major phenotypic changes that is observed during the resistance to EGFR tyrosine kinase inhibitors. However, the mechanism of this transformation remains unclear. In this study, we found a small de novo SCLC component in surgically resected specimens of EGFR-mutated lung adenocarcinoma before EGFR tyrosine kinase inhibitor treatment. By using laser microdissection and whole-exome sequencing, TP53 loss of heterozygosity was found to be possibly involved in SCLC transformation.

Ejemplares similares